卵巢高反应患者全胚冷冻临床应用研究

目的 探讨卵巢高反应患者新鲜移植周期与冻融胚胎移植(frozen-thawed embryo transfer, FET)周期妊娠结局的差异,了解促排卵药物对新鲜周期子宫内膜容受性的影响。方法 回顾性分析2011年1月至2013年12月在中国医科大学附属盛京医院生殖中心促排卵周期行新鲜胚胎移植(582例)和全部胚胎冷冻再行FET(167例)周期的临床妊娠率、生化妊娠率、种植率、胚胎停育率、异位妊娠率、流产率、持续妊娠率和多胎妊娠率。结果 582例促排卵周期新鲜胚胎移植与167例FET周期比较临床妊娠率（42.44% vs. 69.46%）,生化妊娠率（7.22% vs. 2.99%）,种植率（28.27% vs. 48.99%）,胚胎停育率（8.10% vs. 7.76%）,异位妊娠率（5.26% vs. 4.31%）,流产率（8.10% vs. 6.90%）,持续妊娠率（34.19% vs. 59.88%）,多胎率（35.22% vs. 37.93%）。组间比较临床妊娠率、生化妊娠率、种植率、持续妊娠率差异均有统计学意义(P<0.05)。结论 全胚冷冻再行冻融周期移植可显著提高卵巢高反应患者临床妊娠率、种植率及持续妊娠率,不增加多胎率的发生,可获得更为理想的妊娠结局。新鲜周期高雌激素可能对子宫内膜容受性有损害作用。     

处理后前向运动精子总数对夫精人工授精妊娠率的影响

目的:探讨处理后前向运动的精子总数(post-wash total mobile sperm count,PTMC)对夫精宫腔内人工授精(intrauterine insemination,IUI)妊娠率的影响。方法:回顾性分析因男方因素行IUI治疗的不孕夫妇的数据,并比较了PTMC(3.0~9.9)×10~6(研究组)及PTMC≥10×10~6(对照组)患者的IUI妊娠率。结果:共纳入139例(274个周期)患者。其中研究组87个周期,平均PTMC为(6.2±1.7)×10~6,对照组187个周期,平均PTMC为(25.6±13.7)×10~6,组间周期妊娠率差异无统计学意义(P0.05)。在139例患者中,有32例患者(55个周期)PTMC始终10×10~6,83例患者(149个周期)PTMC始终≥10×10~6,在4个周期后患者的累积妊娠率(cumulative pregnancy rate,CPR)分别为15.6%(5/32)和25.3%(21/83),组间比较也无统计学差异(P0.05)。在PTMC始终10×10~6组,在第4周期没有妊娠发生。结论:对于因男方因素行辅助生殖技术助孕治疗的患者,即使PTMC10×10~6也可以尝试IUI,并能获得较好的妊娠率,但对于反复PTMC10×10~6患者,不建议患者多次反复尝试,在经过3次IUI后仍未孕者,可考虑行IVF助孕治疗。     

The Effect of Intramural Myomas Without an Intracavity Component on In Vitro Fertilization Outcomes in Single Fresh Blastocyst Transfer Cycles

Study Objective

To assess clinical pregnancy rate (CPR) and live birth rate (LBR) in the presence of non–cavity-deforming intramural myomas in single fresh blastocyst transfer cycles.

Voice outcomes of polyacrylamide hydrogel injection laryngoplasty

OBJECTIVES: Polyacrylamide hydrogel (PAAG, Aquamid) is widely used as permanent facial tissue filler during facial plastic surgery. In this study, we examined the long-term effects and safety aspects of PAAG as a vocal fold augmentation material for patients with permanent unilateral vocal cord paralysis. STUDY DESIGN: Prospective clinical trials. METHODS: PAAG injection laryngoplasty was performed in 34 consecutive patients with permanent unilateral vocal cord paralysis. Percutaneous injection was performed under local anesthesia into the vocalis muscle using disposable 25 gauge long needles. Of the 34 patients, 16 completed acoustic, perceptual, stroboscopic, and subjective evaluations prior to the injection and at 6 and 12 months after the injection. RESULTS: Acoustic and perceptual parameters (GRBAS [Overall grade of dysphonia, Roughness, Breathiness, Aesthenia, Strain], Maximal phonation time [MPT], jitter, and shimmer) were significantly improved (P < .05) after injection and remained stable over 12 months. The grades of mucosal waves and glottic closure were also significantly improved (P < .01). The voice handicap index (VHI), as well as the visual analogue scale (VAS) of hoarseness and aspiration significantly improved over 12 months. No adverse effects were observed except for a decrease in the mucosal wave of one patient, after injection into a superficial area of the vocal fold. CONCLUSION: Based on the preliminary results of this trial, PAAG appears to be a long-lasting and safe injection material that is suitable for the treatment of glottal insufficiency caused by permanent unilateral vocal cord paralysis.     

阻塞性睡眠呼吸暂停低通气综合征患者不同刺激率ABR结果分析

目的：探讨高刺激率ABR对阻塞性睡眠呼吸暂停低通气综合征（obstructive sleep apnea－hypopnea syndrome,OSAHS）患者听力评估的价值及其与低氧血症的相关性。方法对39例（78耳）OSAHS患者（中度5例、重度34例）和34例（68耳）正常成年人分别进行11．1、31．1、51．1次/秒刺激率的听性脑干反应（ABR）测试,比较组间结果,并与多导睡眠监测呼吸暂停低通气指数（AHI）、最低血氧饱和度（LSaO2）、平均血氧饱和度（MSaO2）、氧饱和度≤90％的时间占总监测时间的百分比（SIT90）、氧饱和度≤80％的时间占总监测时间的百分比（SIT80）进行相关性分析。结果在11．1次/秒刺激率时OSAHS组ABR波Ⅴ潜伏期（5．79±0．22 ms）较对照组（5．67±0．24 ms）延长;31．1次/秒刺激率时OSAHS组ABR 波Ⅰ潜伏期（1．85±0．18 ms）、波Ⅴ潜伏期（5．98±0．19 ms）均较对照组（分别为1．76±0．16 ms、5．82±0．24 ms）延长;在51．1次/秒刺激率时OSAHS组ABR波Ⅰ潜伏期（1．94±0．26 ms）、波Ⅴ潜伏期（6．09±0．25 ms）较对照组（分别为1．83±0．15 ms、5．99±0．24 ms）延长。刺激率由11．1次/秒升高至31．1次/秒时,OSAHS 组波Ⅰ潜伏期延长,ΔⅠ31．1－11．1（0．12±0．17ms）较对照组（0．07±0．11 ms）长,刺激率由11．1次/秒升高至51．1次/秒时,OSAHS组波Ⅰ潜伏期延长,ΔⅠ51．1－11．1（0．21±0．25 ms）较对照组（0．15±0．10 ms）长。ΔⅠ31．1－11．1与LSaO2负相关（r＝－0．24）,与SIT90（r＝0．23）、SIT80（r＝0．27）正相关;ΔⅠ51．1－11．1与LSaO2（r＝－0．33）、MSaO2（r＝－0．35）负相关,与SIT90（r＝0．37）、SIT80（r＝0．29）正相关;以上差异及相关性均有统计学意义（p＜0．05）。结论高刺激率ABR可发现中度及重度OSAHS患者耳蜗及听神经近耳蜗段的损伤。     

颈段气管袖状切除术的临床分析

目的：总结颈段气管袖状切除术的经验,以提高颈段气管肿瘤的治疗效果。方法：回顾性分析1985-01～2006—12颈段气管袖状切除术治疗的12例患者,其中腺样囊性癌6例,鳞状细胞癌4例,腺癌1例,颈段气管软化塌陷1例。气管切除长度3～6cm,其中气管切除长度≥5cm5例,喉体松解术7例,甲状腺次全切除术3例。用正常甲状腺组织包绕气管及吻合口9例,未包绕3例。结果：所有患者喉功能均得以保留,发声正常,吻合口生长良好,受到分离的气管段色泽红润。3年生存率为85．37％,5年生存率为56．61％。结论：颈段气管袖状切除术符合气管肿瘤的治疗原则。改进的术式有利于气管吻合口的愈合,有利于更干净、彻底地切除气管肿瘤。     

中-重度不典型增生喉癌癌前病变的治疗探讨

目的提高对中-重度不典型增生喉癌癌前病变的认识,选择恰当的方法治疗中-重度不典型增生喉癌癌前病变。方法选取经病理证实的29例喉中-重度不典型增生癌前病变患者,其中26例采用喉内镜下声带黏膜剥脱术治疗,3例采用喉裂开下喉部分切除术治疗。所有患者术后均随访3年以上,若出现恶变者则至恶变时为此研究随访结束时间。结果 17例一次性治愈;2例复发,采用喉裂开下喉部分切除术治愈;10例癌变,此患者之后按肿瘤分期分别行开放性手术。结论病理为中-重度不典型增生的喉癌癌前病变恶变率高,采用支撑喉镜下声带黏膜剥脱术治疗喉癌癌前病变仍有较高的治愈率,但术后必须严格随诊。     

Efficiency and durability of hyaluronic acid of different particle sizes as an injectable material for VF augmentation

Conclusion: The results of the present investigation suggest that modification of HA could improve efficiency and durability in augmentation laryngoplasty. Objectives: Injection laryngoplasty (IL) is one of the most suitable options for treatment of glottic insufficiency, which is caused by vocal fold (VF) paralysis, atrophy, or scarring. Hyaluronic acid (HA) is a widely used material for VF injection. This study was intended to evaluate the durability and efficiency of HA of different particle sizes for VF augmentation. Methods: Three types of HA, Restylane®, monophasic low-viscosity, and unequal particle-sized middle-viscosity HA were injected into the left VF of three groups with eight rabbits each. Results: After 6 and 10 weeks, the injected site was evaluated endoscopically, histologically, radiologically, and functionally. None of the 24 rabbits showed any signs of respiratory distress. Computed tomography (CT) images and endoscopic evaluation revealed sufficient augmented volume of the injected VF in all treated groups 6 weeks after the injection. Histological data at week 10 showed that unequal particle-sized HA did not migrate from its original injection site, while other HAs migrated to the periphery of the arytenoid cartilage. Videokymographic analysis showed more favorable vibrations of unequal particle-sized HA injected VF mucosa 10 weeks post-injection, compared to the other treatment groups.     

Ab舒血宁注射液对急性脑梗死患者血浆C反应蛋白和血栓素B2的影响

目的:观察舒血宁注射液对急性脑梗死患者血浆C反应蛋白(CRP)和血栓素B2(TXB2)水平的影响,探讨舒血宁注射液治疗急性脑梗死的机制。方法将90例患者急性脑梗死患者随机分为舒血宁治疗组和丹参治疗组,在治疗前及治疗后第15天检测血浆CRP(免疫比浊法)和TXB2(双抗体夹心ELISA法)含量。结果急性脑梗死病人治疗前血浆CRP、TXB2的含量较健康对照组明显增加(P<0.05)。经舒血宁、复方丹参注射液治疗后血浆CRP、TXB2的含量明显下降(P<0.05),但仍然高于健康对照组(P<0.05)。与丹参治疗组相比,舒血宁治疗组CRP、TXB2的下降更为明显(P<0.05)。结论舒血宁注射液治疗急性脑梗死的疗效可能与使急性脑梗死患者血浆CRP和TXB2水平下降有关。     

盐酸吡格列酮固体制剂的溶出度考察

目的：建立一种对盐酸吡格列酮固体制剂体外溶出情况区别能力更强的溶出度测定方法。方法：通过比较盐酸吡格列酮固体制剂在不同介质中（pH1．0、pH2．0等）的溶出差异性及与参比制剂的体外溶出曲线的相似性采确定溶出方法。结果：采用桨法,以pH2．0缓冲液为溶出介质,转速为50r·min^-1的溶出条件下,国产盐酸吡格列酮固体制剂与参比制剂的溶出行为存在很大差异,而且不同生产厂家的溶出行为具有明显区别。结论：国产制剂的内在质量与参比制剂仍存在较大差异,确定的溶出方法对制剂体外溶出度的区别能力更强。